ADG106

About Adagene

Adagene's mission is to transform antibody drug discovery and development through its proprietary AI-powered Dynamic Precision Library (DPL) platform. The company has achieved significant validation through strategic collaborations with global pharmaceutical partners and has advanced a pipeline of nine candidates, including its lead SAFEbody-masked anti-CTLA-4 program, ADG126, which has shown a compelling clinical safety profile. Its strategy focuses on leveraging computational design to create precision biologics with enhanced therapeutic indices, aiming to deliver first- or best-in-class therapies in oncology while monetizing its platform through partnerships.

Therapeutic Areas